• Users Online: 99
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 4  |  Issue : 2  |  Page : 30-44

Microalbuminuria in hemoglobinopathy patients who are taking Deferasirox

1 Consultant Physician, Alsaddir Teaching Hospital
2 Department of Pharmacology, College of Pharmacy, University of Basrah
3 Internist Physician, Alsaddir Teaching Hospital

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Background: Chelation therapy which is needed to prevent or reverse iron overload may also affect renal function in patients with hemoglobinopathy. The early indicator as well as predictor of nephropathy and glomerular damage among patients with sickle cell disease and thalassemia is microalbuminuria (MA). Objective: This study was aimed to estimate the frequency of MA in patients with thalassemia and sickle cell syndromes who were taking deferasirox and to find if any relationship between the level of MA and other parameters like age, gender, type of hemoglobinopathy, serum creatinine and ferritin levels. Materials and methods: This is a clinical study in hemoglobinopathy patients that taking deferasirox (oral iron chelator) in Center For Hereditary Blood Diseases (HBDC) in Basrah during the period between April 2013 and February 2014. The informations were took from patients by a questionnaire form and urine samples were collected from each patient for measurement of microalbuminuria by Enzyme-linked immunosorbent assay method (ELISA) and blood samples for biochemical tests including serum creatinine and ferritin. Results: In this study, 100 patients were 38 males and 62 females with mean of age was 25.74±10.59 years. MA detected in 31 patients and it was more among males (36.8%, 37.0 mg/ml) as compared to (27.4%, 26.0 mg/ml) of female and more in sickle cell syndrome (35%, 35.0 mg/ml) as compared to (25%, 24.0 mg/ml) of thalassemia patients and more in patients with age <30 years (35.5%, 35.5 mg/ml) as compared to patients with age ≥ 30 years (16.7%, 22.0 mg/ml). There was no significant relationship between MA and serum creatinin or serum ferritin levels but significant relationship was found between MA level and age. Conclusion: In conclusion, the study might reflect the relatively low prevalence rate of MA among non- protienuria, deferasirox-taking patients with hemoglobinopathies in Basrah. Microalbuminuria affected by many factors including age, gender, diagnosis and other factors.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded184    
    Comments [Add]    

Recommend this journal